Related references
Note: Only part of the references are listed.The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?
Bing Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Guillermo Montalban-Bravo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Excess mortality in the myelodysplastic syndromes
Meritxell Nomdedeu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
A. Nazha et al.
LEUKEMIA (2017)
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
M. G. Della Porta et al.
LEUKEMIA (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3) (q21q26.2) and del(11q)
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2017)
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
Ivan Martin et al.
BLOOD CANCER JOURNAL (2017)
Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing
Yuanyuan Xu et al.
ONCOTARGET (2017)
Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes
Margot F. van Spronsen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
Fernando Ramos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome
Rashmi Kanagal-Shamanna et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Myelodysplastic syndromes: Contemporary review and how we treat
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Brian C. Shaffer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment
N. Gangat et al.
BLOOD CANCER JOURNAL (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome
Ruixian Xing et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
Chien-Chin Lin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
T-C Chen et al.
BLOOD CANCER JOURNAL (2014)
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Olivier Kosmider et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
RUNX1 gene mutation in primary myelodysplastic syndrome -: the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
Chien-Yuan Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Share Paper
